Impact of different modifiable factors on hearing function in type 1 and type 2 diabetic subjects. A preliminary study
More details
Hide details
Medical Faculty, Institute of Nursing and Health Sciences, University of Rzeszow, Poland
Department of Pediatrics Otolaryngology Phoniatrics and Audiology, Medical University, Lublin, Poland
Department of Endocrinology, Medical University, Lublin, Poland
Ann Agric Environ Med. 2013;20(4):773–778
Introduction and objective:
Hearing impairment in diabetic subjects is more prevalent than in the general population. Ageing, noise exposure and smoking are known as risk factors of hearing loss. The aim of this study was to assess whether other factors, such as HbA1c, blood pressure, serum lipids and BMI have an impact on hearing function among relatively young diabetic subjects.

Material and Methods:
58 patients, 31 with type 1 diabetes and 27 with type 2 diabetes, aged <45 years, with diabetes duration < 10 years and without overt hearing impairment were included. In all subjects, vital signs, laboratory tests, pure-tone audiometry and trancient-evoked otoacoustic emissions (TEOAE) were evaluated.

Hearing impairment was revealed in 20 subjects. This group had a lower HDL-cholesterol level compared with normal hearing patients (44.2 mg/dl vs. 57.6 mg/dl, p=0.007). Absence of otoacoustic emissions was diagnosed in 16 subjects. These patients also had a lower HDL-cholesterol level compared with subjects with TEOAE present (45.4 mg/dl vs. 55.2 mg/dl, p=0.018). Hearing threshold was inversely correlated with HDL-cholesterol level, and positively correlated with triglycerides. Patients with HDL-cholesterol level ≥50 mg/dl had lower hearing threshold at frequencies 0.5–12 kHz, as well as higher TEOAE amplitude. Subjects with triglycerides above median had a higher hearing threshold at frequencies 0.5–12 kHz, as well as lower TEOAE amplitude. Patients with elevated BMI (≥25 kg/m2) had a higher hearing threshold at frequencies 2–12 kHz, as well as lower TEOAE amplitude.

Hearing impairment is frequent among relatively young diabetic subjects. The preseted study reveals that factors like HDL-cholesterol, triglycerides, and BMI may affect hearing function in this group.

Brant LJ, Fozard JL. Age changes in pure-tone hearing thresholds in a longitudinal study of normal human aging. J Acoust Soc Am. 1990; 88: 813–820.
Fransen E, Topsakal V, Hendrickx J-J, et al. Occupational noise, smoking, and a high body mass index are risk factors for age-related hearing impairment and moderate alcohol consumption is protective: A European population-based multicenter study. J Assoc Res Otolaryngol. 2008; 9: 264–276.
Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: Audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med. 2008; 149: 1–10.
Taylor IG, Irwin J. Some audiological aspects of diabetes mellitus. J Laryngol Otol. 1978; 92: 99–113. 5. Ferrer JP, Biurrun O, Lorente J, et al. Auditory function in young patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 1991; 11: 17–22.
Cullen JR, Cinnamond MJ. Hearing loss in diabetics. J Laryngol Otol. 1993; 107: 179–182.
Virtaniemi J, Laakso M, Nuutinen J, et al. Hearing thresholds in insulindependent diabetic patients. J Laryngol Otol. 1994; 108: 837–841.
Pessin ABB, Martins RHG, Pimenta WDP, Simões ACP, Marsiglia A, Amaral AV. Auditory evaluation in patients with type 1 diabetes. Ann Otol Rhinol Laryngol. 2008; 117: 366–370.
Dąbrowski M, Niedzielska G, Nowakowski A. The auditory organ involvement in type 1 diabetes mellitus. Endokrynol Pol. 2011; 62: 138–144.
Malucelli DA, Malucelli FJ, Fonseca VR, et al. Hearing loss prevalence in patients with diabetes mellitus type 1. Braz J Otorhinolaryngol. 2012; 78: 105–115.
Di Leo MAS, Di Nardo W, Cercone S, et al. Cochlear dysfunction in IDDM patients with subclinical peripheral neuropathy. Diabetes Care 1997; 20: 824–828.
Lisowska G, Namyslowski G, Morawski K, et al. Early identification of hearing impairment in patients with type 1 diabetes mellitus. Otol Neurotol. 2001; 22: 316–320.
Ottaviani F, Dozio N, Neglia CB, et al. Absence of otoacoustic emissions in insulin-dependent diabetic patients. Is there evidence for diabetic cochleopathy? J Diabetes Complications 2002; 16: 338–343.
Hilali A, Das V, Boulton A. A study of otoacoustic emissions in type 1 diabetes mellitus. Audiol Med. 2003; 1: 255–260.
Cruickshanks KJ, Klein R, Klein BEK, Wiley TL. Association of NIDDM and hearing loss. Diabetes Care. 1998; 21: 1540–1544.
Kakarlapudi V, Sawyer R, Staecker H. The effect of diabetes on sensorineural hearing loss. Otol Neurotol. 2003; 24: 382–386.
Sakuta H, Suzuki T, Yasuda H, Ito T. Type 2 diabetes and hearing loss in personnel of the Self-Defense Forces. Diabetes Res Clin Pract. 2007; 75: 229–234.
Austin DF, Konrad-Martin D, Griest S, McMillan GP, McDermott D, Fausti S. Diabetes-related changes in hearing. Laryngoscope 2009; 119: 1788–1796.
Lerman-Garber I, Cuevas-Ramos D, Valdés S, et al. Sensorineural hearing loss – a common finding in early-onset type 2 diabetes mellitus. Endocr Pract. 2012; 18: 549–557.
Bainbridge KE, Hoffman HJ, Cowie CC. Risk factors for hearing impairment among U.S. adults with diabetes. National Health and Nutrition Examination Survey 1999–2004. Diabetes Care. 2011; 34: 1540–1545.
Duck SW, Prazma J, Bennett PS, Pillsbury HC. Interaction between hypertension and diabetes mellitus in the pathogenesis of sensorineural hearing loss. Laryngoscope 1997; 107: 1596–1605.
Jørgensen MB, Buch NH. Studies on inner ear function and cranial nerves in diabetics. Acta Otolaryngol. 1961; 53: 350–364.
Erdem T, Ozturan O, Cem Miman M, Ozturk C, Karatas E. Exploration of the early auditory effects of hyperlipoproteinemia and diabetes mellitus using otoacoustic emissions. Eur Arch Otorhinolaryngol. 2003; 260: 62–66.
Kutz Jr JW, Mullin G, Campbell KCM. Audiology, pure-tone testing [article online]. Available from: article/1822962-overview, updated 1 March 2012; Accessed 9 September 2012.
Campbell KCM, Mullin G. Otoacoustic emissions [article online]. Available from: overview, updated 15 June 2012; Accessed 9 September 2012.
Śliwińska-Kowalska M, Kotyło P, Morawski K. Emisje otoakustyczne. In: Śliwińska-Kowalska M. red. Audiologia kliniczna. Mediton Oficyna Wydawnicza. Łódź 2005: 149–162.
Pruszewicz A. Audiologia kliniczna. Zarys. Wyd. 3. Wydawnictwa Akademii Medycznej, Poznań 2003.
de Moraes Marchiori LL, de Almeida Rego Filho E, Matsuo T. Hypertension as a factor associated with hearing loss. Braz J Otorrinolaringol. 2006; 72: 533–540.
Narlawar UW, Surjuse BG, Thakre SS. Hypertension and hearing impairment in workers of iron and steel industry. Indian J Physiol Pharmacol. 2006; 50: 60–66.
Esparza CM, Jáuregui-Renaud K, Morelos CMC, et al. Systemic high blood pressure and inner ear dysfunction: A preliminary study. Clin Otolaryngol. 2007; 32: 173–178.
Torre III P, Cruickshanks KJ, Klein BEK, Klein R, Nondahl DM. The association between cardiovascular disease and cochlear function in older adults. J Speech Lang Hear Res. 2005; 48: 473–481.
Evans MB, Tonini R, Do Shope C, et al. Dyslipidemia and auditory function. Otol Neurotol. 2005; 27: 609–614.
Chang N-C, Yu M-L, Ho K-Y, Ho C-K. Hyperlipidemia in noise-induced hearing loss. Otolaryngol Head Neck Surg. 2007; 137: 603–606. 34. Suzuki K, Kaneko M, Murai K. Influence of serum lipids on auditory function. Laryngoscope 2000; 110: 1736–1738.
Preyer S, Baisch A, Bless D, Gummer AW. Distortion product otoacoustic emissions in human hypercholesterolemia. Hear Res. 2001; 152: 139–151.
Satar B, Özkaptan Y, Sürücü HS, Öztürk H. Ultrastructural effects of hypercholesterolemia on the cochlea. Otol Neurotol. 2001; 22: 786–789.
Bainbridge KE, Cheng YJ, Cowie CC. Potential mediators of diabetesrelated hearing impairment in the U.S. population. National Health and Nutrition Examination Survey 1999–2004. Diabetes Care 2010; 33: 811–816.